Metformin Hydrochloride + Sitagliptin
This formulation combines two antihyperglycemic agents with different but complementary mechanisms to improve glycemic control in patients with type 2 diabetes. It contains sitagliptin, a DPP-4 (dipeptidyl peptidase-4) inhibitor, and metformin hydrochloride, a biguanide antidiabetic agent.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
This combination medicine is prescribed alongside diet and exercise to help improve blood sugar control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is considered appropriate.
Important limitations of use:
The dosage should be individualized according to the patient’s current treatment regimen, response, and tolerability, without exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin.
Recommended starting doses:
Switching from other oral antidiabetic therapies should be done carefully with appropriate monitoring because glycemic control may fluctuate.
Patients transitioning between immediate-release and extended-release formulations should maintain the same total daily dose of sitagliptin and metformin.
When used together with insulin or insulin secretagogues such as sulfonylureas, dose reduction of those agents may be necessary to minimize the risk of hypoglycemia.
Sitagliptin:
Supportive treatment should be provided, including removal of unabsorbed drug and ECG monitoring. Sitagliptin is moderately removed by hemodialysis.
Metformin:
Large overdoses may lead to severe lactic acidosis. Metformin is dialyzable and hemodialysis may help remove accumulated drug. Pancreatitis may also occur in overdose situations.
Symptoms may include malaise, muscle pain, breathing difficulty, abdominal discomfort, drowsiness, low body temperature, and laboratory abnormalities such as elevated lactate levels and low blood pH. Immediate discontinuation and hospitalization are required if lactic acidosis is suspected.
Common adverse effects may include:
Pregnancy:
Classified as Pregnancy Category B. Adequate studies in pregnant women are lacking. Use during pregnancy only if clearly needed.
Lactation:
It is unknown whether sitagliptin passes into human breast milk. Caution is advised when administering this medication to breastfeeding mothers.
Store below 25°C in a dry place away from heat and light. Keep out of the reach of children. Use only under the prescription of a registered physician.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.